Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Roivant, Pfizer shares rise as Roche agrees to buy immunology company for $7.1 billion
08:36am, Monday, 23'rd Oct 2023
Shares of Roivant Sciences Ltd. ROIV, -1.13% and Pfizer Inc. PFE, -1.73% gained ground premarket on Monday after Roche Holding AG RHHBY, +0.51% agreed to buy immunology company Telavant for $7.1 billi
Roche Agrees $7.1 Billion for Drug Company
05:40am, Monday, 23'rd Oct 2023
It will buy immunology company Telavant Holdings from Roivant Sciences and Pfizer.
Roche splashes US$7.1 billion on new irritable bowel drug
04:44am, Monday, 23'rd Oct 2023
Roche has agreed to pay US$7.1 billion for an early-stage inflammatory bowel disease treatment developed by US rivals Roivant and Pfizer. For its money, the Swiss group will get the rights to develop
Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant Holdings
01:44am, Monday, 23'rd Oct 2023
Swiss health care company Roche announced it would acquire Telavant Holdings Monday, in a deal worth $7.1 billion.
Roche buys Telavant Holdings for $7.1 billion
01:37am, Monday, 23'rd Oct 2023
Roche on Monday said it will buy Telavant, a developer of a new treatment for inflamatory bowel diseases, for an initial $7.1 billion from American biopharma company Roivant Holdings and Pfizer Inc.
India is a ‘slow trundling elephant' but a viable alternative to China, says veteran investor David Roche
11:25pm, Sunday, 22'nd Oct 2023
Veteran Investor David Roche said India has been aligning itself with the "democratic alliances" of the "richest and most vibrant economies" in the world.
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
06:00am, Saturday, 21'st Oct 2023
Pfizer's revenue has taken a big hit because of lower COVID-19-related sales. Roche just released third-quarter earnings.
Roche (RHHBY) Nine Months' Sales Fall on Lower COVID-19 Test Sale
12:47pm, Thursday, 19'th Oct 2023
Roche (RHHBY) reports a sales decline in the first nine months of 2023 as COVID-19-test sales continue to dent its top line. Currency rate fluctuations also impact its results.
Drug Giant Roche Skids As Covid Products Decline Weighs On Sales, Guidance
10:04am, Thursday, 19'th Oct 2023
Roche stock skidded early Thursday after the Swiss drugmaker said declining demand for Covid products weighed on third-quarter sales.
Roche's 9M sales down 6% on currency headwinds, drop in COVID sales
01:08am, Thursday, 19'th Oct 2023
Roche said nine-month sales slipped 6% to 44.1 billion Swiss francs ($49.1 billion), hit by a sharp decline in sales of COVID-19 products and as a strong Swiss franc weighed on the value of overseas s
Roche's (RHHBY) MS Drug Reduces Brain Lesions in Phase II Study
02:17pm, Monday, 16'th Oct 2023
Roche (RHHBY) presents new data from a phase II study, which shows that fenebrutinib is brain penetrant and reduces brain lesions in people with relapsing multiple sclerosis.
Roche's (RHHBY) Vabysmo Positive in Late-Stage RVO Studies
01:32pm, Tuesday, 10'th Oct 2023
Roche (RHHBY) Vabysmo maintains vision improvements with extended treatment intervals of up to four months in phase III studies for retinal vein occlusion.
Basel, 02 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new data for OCREVUS® (ocrelizumab) and investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib for multiple scl
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will present new data for Ocrevus® (ocrelizumab) and investigational Bruton's tyrosi
Biogen gets FDA approval for biotech treatment similar to Roche's Actemra
04:25pm, Friday, 29'th Sep 2023
Biogen Inc. BIIB, -0.32% said late Friday the Food and Drug Administration approved its biosimilar version of Roche ROG, +0.30% ‘s arthritis treatment Actemra. Biogen said its treatment Tofidence, o
